ADC– tag –

Oncology is the tip of the spear for China-origin innovation in global partnering. This article gives you a bird’s-eye view of the major deals, then goes deep into the operating logic behind ADCs, bispecific antibodies, checkpoint inhibi...

Claudin18.2 (CLDN18.2)-directed ADCs are rapidly emerging as a cornerstone in the treatment of advanced gastric and gastroesophageal junction (GEJ) cancers. Beyond SHR-A1904 and IBI343, several other candidates such as CMG901, EO-3021, a...

Two phase 1 trials—SHR-A1904 and IBI343—have propelled the clinical development of CLDN18.2-directed ADCs. This article provides a head-to-head comparison of their design, efficacy, safety, and positioning relative to zolbetuximab and ot...

In this article, we summarize the phase 1 trial of IBI343, reported in Nature Medicine (July 2025), focusing on its structural innovations, safety, efficacy, and position within the landscape of Claudin18.2-targeted ADCs. Drug Profile: M...

In Part 1 of our feature, we explored Enhertu’s groundbreaking pharmacological profile and its role in launching the second ADC boom. In this concluding part, we shift focus to intellectual property strategies, patent lifespans, and the ...

Antibody–drug conjugates (ADCs) targeting Claudin18.2 (CLDN18.2) have gained increasing attention as a novel therapeutic approach for advanced gastric and gastroesophageal junction (GEJ) cancers. Here, we summarize the phase 1 trial resu...

Antibody-drug conjugates (ADCs) have emerged as one of the most exciting modalities in oncology. Among them, HER2-targeted ADCs have undergone a dramatic transformation with the arrival of Daiichi Sankyo and AstraZeneca’s Enhertu, sparki...

This series provides an in-depth review of the current landscape of Claudin18.2 (CLDN18.2)-targeted antibody–drug conjugates (ADCs) in gastric and gastroesophageal junction (GEJ) cancers. Structured into five parts, it covers pivotal cli...

This article is the second half of the Morningglorysciences Summer Beginner Series Grand Summary. In Part 1, we reviewed anti-obesity drugs, ADCs, and In vivo CAR-T cell therapy, comparing their strengths and shared challenges. Here in P...

This article is the first half of the Morningglorysciences Summer Beginner Series Grand Summary. We revisit three major therapeutic modalities—anti-obesity drugs, antibody-drug conjugates (ADCs), and In vivo CAR-T cell therapy—highlighti...

This article is the comprehensive summary of our Morningglorysciences Summer Beginner Series on Antibody-Drug Conjugates (ADCs). Throughout the series, we introduced the basics, design principles, historical improvements, and clinical ap...

Over the past few years, the landscape of Antibody-Drug Conjugates (ADCs) has undergone a dramatic transformation, shifting from a niche therapeutic approach to a central pillar of oncology innovation. This bonus chapter highlights recen...

Antibody-drug conjugates (ADCs) deliver highly potent cytotoxic agents specifically to cancer cells, representing a breakthrough in targeted therapy. This article explains the final stage of ADC function—how the linker system releases th...

In Antibody-Drug Conjugates (ADCs), antibodies serve as targeting agents that deliver drugs to cancer cells. This article focuses on the "Variable Region," the key structure that enables antibodies to specifically recognize cancer antige...

Summer Special｜Beginner-Friendly Intro Series Vol.2 (Part 1)What Are Antibodies? The Origin Story of ADCs – A Precision Cancer Weapon Welcome to Part 1 of our Summer Special Beginner Series Vol.2 on Morningglorysciences.This time, we’ll...

Strategic Review: Investing in Marketed Products and Next-Gen Modalities Astellas Pharma has executed a series of acquisitions and collaborations from 2015 to 2025 focused on immuno-oncology, ophthalmology, neurology, and gene therapy. K...

Strategic Review: From Biologics to Rare Diseases, Oncology, and RNA Innovation Over the past decade, Amgen has expanded beyond its legacy focus on bone and inflammatory diseases to invest heavily in oncology, RNA therapies, and rare dis...

Strategic Review: Investing in ADCs, Rare Diseases, and Biomanufacturing Capabilities AstraZeneca has expanded significantly in oncology through antibody and ADC partnerships, including a high-profile collaboration with Japan’s Daiichi S...

Strategic Review: Beyond Keytruda—Pivot to Next-Gen Modalities Merck (MSD in the U.S.) built a strong oncology franchise with Keytruda. As patents expire, Merck is investing in ADCs, RNA therapies, cell therapy, and precision immunology ...

[FDA Accelerated Approval] Datroway by Daiichi Sankyo approved for EGFR-mutated non-small cell lung cancer (June 23, 2025) On June 23, 2025, the U.S. FDA granted accelerated approval to Datopotamab deruxtecan-dlnk (Datroway) for adults w...